SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech for less than cash value
An SI Board Since April 2002
Posts SubjectMarks Bans
684 125 0
Emcee:  RWReeves Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
534Good stuff. I'll have to poke around on that, would be curious what % of revrkrw-8/6/2019
533Totally agree. But do think there are a few CEOs of cash-rich biotechs who’ve shBulbaMan-8/5/2019
532That’s business development and completely different. BD is hard, not so many arrkrw18/5/2019
531The Biotech Buyouts table referenced in the header of the iHub BV board includesDewDiligence_on_SI18/5/2019
530Thanks RKRW, but not the kind of deal that I’m looking for. ;~) Amount of RLM caBulbaMan-8/5/2019
529I stand corrected, came across this one that traded their cash for equivalent shrkrw-8/5/2019
528CABG liquidation: investorshub.advfn.comDewDiligence_on_SI-7/30/2019
527CABG but it's a while ago. And heart valve replacement rather than drug.Lance Bredvold-7/30/2019
526>>>I guess IMDZ had something worth buying... As you may remember, my BulbaMan-7/29/2019
525I guess IMDZ had something worth buying and a willing buyer. Then there are corkrw-7/27/2019
524@buysidebio posted this on Twitter recently: "Biotech & Pharma names wbmaz001-7/27/2019
523For sure, the CEO’s reputation for deal-making and self-dealing would be a factoBulbaMan-7/27/2019
522I can't remember the last biotech that did a simple dissolve and return the rkrw17/27/2019
521That’s not surprising. But I’m guessing there are more than a handful that have BulbaMan-7/27/2019
520Many of the names are less cash rich, than market cap poor. rkrw17/27/2019
519Thanks for posting the list! I wonder if it would be useful to check for the ageBulbaMan-7/27/2019
518First hit, Jounce with a $50m upfront from Celgene,.rkrw17/24/2019
51762 names below cash. Bear in mind, numbers aren't updated for Q2 ending cashrkrw17/23/2019
516All disclosed before but here's what they get as a reward for running the corkrw-6/4/2019
515VICL actually got much more equity in the merged company (40%) than you typicallDewDiligence_on_SI-6/3/2019
514Wow. wtf. A very deserved -20%. brickellbio.comkeokalani'nui-6/3/2019
513Oops. Thanks. 7.2m additional shares, as you point out.keokalani'nui-4/25/2019
512I think you mean Cash>>MC. VICL has lots of pre-funded warrants out, whichBulbaMan-4/25/2019
511In for some Vical. Ceased development program, under 'strategic review',keokalani'nui14/25/2019
510I've added a new column for 'Study References and Results'. Along wibmaz00113/29/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News